Yi Zhang | Health Sciences | Best Researcher Award

Posted on by sciencefather

Prof. Yi Zhang | Health Sciences | Best Researcher Award šŸ†

Director/Academic Vice President at Biotherapy Center, The First Affiliated Hospital of Zhengzhou University/Zhengzhou University School of Medical SciencesšŸŽ“

Prof. Yi Zhang is an internationally acclaimed expert in cell and tumor immunotherapy. Serving as Director of the Biotherapy Center at The First Affiliated Hospital of Zhengzhou University, he also holds key leadership roles, including Academic Vice President of the Zhengzhou University School of Medical Sciences and Director of the Zhongyuan Cellular and Immunotherapy Laboratory. With 35 years of research experience across Belgium, the U.S., and China, Prof. Zhang has pioneered breakthrough therapies, such as genetically engineered CAR-T cells for solid tumors, and holds 16 patents. His work has made significant impacts in reducing immune suppression and improving cancer treatment efficacy worldwide.

Professional ProfileĀ 

Education šŸŽ“:

Prof. Yi Zhang has a profound academic foundation in medical sciences, gained through decades of experience and study in Belgium, the United States, and China. His extensive education and training have built the groundwork for his pioneering research in cell and tumor therapy.

Work Experience šŸ’¼:

Prof. Zhang is the Director of the Biotherapy Center at The First Affiliated Hospital of Zhengzhou University, where he also serves as the Academic Vice President for Zhengzhou University’s School of Medical Sciences and Director of the Zhongyuan Cellular and Immunotherapy Laboratory. Over a 35-year career, he has developed innovative therapies and led cutting-edge research in cell therapy, accumulating extensive clinical and academic expertise.

 

Skills šŸ”

Known for his skills in genetically engineered cell therapies, Prof. Zhang is a leader in cellular engineering, particularly CAR-T cell technology. His groundbreaking work includes discovering a therapeutic target for solid tumors and developing gene-editing techniques to improve immune responses. His practical expertise in cell culture, immune cell enhancement, and patent development make him a pioneer in clinical biotherapeutics.

Awards and Honors šŸ†

Prof. Zhang has received acclaim globally, being listed among the worldā€™s top 100,000 scientists and recognized by both domestic and international peers for his contributions to immunotherapy. He has successfully converted seven patents, raising over 80 million RMB in transfer amounts, and is frequently invited to international conferences as a distinguished chair or guest of honor.

šŸ¤ Memberships:

Prof. Zhang holds numerous prominent roles, such as Chairman of the Committee on Tumor Immunity and Biotherapy, Chinese Society of Immunology, and Deputy Chairman of the Cancer Biological Therapy Committee under the China Anti-Cancer Association. He also plays leadership roles in the Henan Anticancer Association and Henan Immunological Society, reflecting his commitment to advancing cell therapy on a national and global scale.

Teaching Experience šŸ‘©ā€šŸ«:

Prof. Zhang has contributed significantly to training the next generation of scientists, collaborating with international colleagues to co-train PhD students and mentor young researchers. His commitment to academic growth is evident through his regular academic exchanges and collaborative projects with institutions in Canada, the U.S., and Europe.

Research Focus šŸ”¬:

Prof. Zhangā€™s research is concentrated on tumor immunotherapy and cellular therapy, focusing on advancing CAR-T cell therapies for cancer. His achievements include creating novel immune cell treatments, reducing PD-1 expression to combat immune suppression, and conducting over 52 clinical trials for new cancer therapies, with 29 specifically targeting solid tumors.

ConclusionĀ 

Prof. Yi Zhang stands as an exemplary candidate for the Best Researcher Award due to his substantial contributions to the field of cellular immunotherapy and cancer research. His achievements align closely with the awardā€™s goals of recognizing innovation, impactful research, and contributions to society. With his strengths in pioneering therapy innovations and significant clinical applications, Prof. Zhangā€™s work exemplifies the awardā€™s spirit, making him a distinguished candidate for the Best Researcher Award.

šŸ“š Publilcation

  • “LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8 + T cells for improving anti-PD-1 antibody therapy”
    • Year: 2024-12-31
    • Journal: OncoImmunology
  • “Characteristics and mechanisms of Tā€cell senescence: A potential target for cancer immunotherapy”
    • Year: 2024-11
    • Journal: European Journal of Immunology
  • “CAR T Cells Engineered to Secrete IFNĪŗ Induce Tumor Ferroptosis via an IFNAR/STAT1/ACSL4 Axis”
    • Year: 2024-10-03
    • Journal: Cancer Immunology Research
  • “A single-cell RNA-seq dataset describing macrophages in NSCLC tumor and peritumor tissues”
    • Year: 2024-10-01
    • Journal: Scientific Data
  • “Allogeneic CAR-T cells for cancer immunotherapy”
    • Year: 2024-09-24
    • Journal: Immunotherapy
  • “IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells”
    • Year: 2024-05-03
    • Journal: British Journal of Cancer
  • “Current advances in bacteriaā€based cancer immunotherapy”
    • Year: 2024-02
    • Journal: European Journal of Immunology
  • “Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity”
    • Year: 2023-10-09
    • Journal: Cancer Biology & Medicine
  • “Immunosenescence: molecular mechanisms and diseases”
    • Year: 2023-05-13
    • Journal: Signal Transduction and Targeted Therapy
  • “Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells”
    • Year: 2023-04-28
    • Journal: Signal Transduction and Targeted Therapy

Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher Award

Posted on by sciencefather

Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher AwardšŸ†


Assistant Professor atĀ Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
šŸŽ“

Joanna Jazowiecka-Rakus is an Assistant Professor with a strong focus on advancing cancer research through innovative oncolytic therapies. Her work at the Maria Skłodowska Memorial National Institute of Oncology in Gliwice, Poland, positions her as a leading expert in experimental cancer treatments. Dr. Jazowiecka-Rakusā€™s pioneering research in oncolytic virotherapy and nanocarrier drug delivery aims to address complex cancers like pancreatic adenocarcinoma, glioma, and melanoma. With a reputation for pushing boundaries in cancer treatment, she continues to make strides in developing therapies that offer new hope for patients with challenging diagnoses.

Professional ProfileĀ 

šŸŽ“ Education

Dr. Jazowiecka-Rakus holds a Master of Science in Biology from the Faculty of Biology, University of Silesia, Katowice, Poland (2001), followed by a Ph.D. in Medical Biology from the National Institute of Oncology, Warsaw, Poland (2007). In recognition of her exceptional contributions to cancer research, she earned a D.Sc. (habilitation) in Medical Sciences from the same institution. Her academic path reflects her dedication to enhancing cancer treatment through rigorous scientific training and specialization.

šŸ¢ Work Experience

Throughout her career, Dr. Jazowiecka-Rakus has held esteemed research positions, including her current role as an Assistant Professor at the National Institute of Oncology. Her work has been instrumental in projects funded by prestigious institutions like the International Center for Genetic Engineering and Biotechnology and the National Science Center of Poland. Notably, her research covers a wide spectrum of experimental cancer therapies, including the use of myxoma viruses and mesenchymal stem cells to treat melanoma, ovarian cancer, and glioma. She has also forged valuable collaborations with global institutions, such as the Biodesign Institute at the University of Arizona, Tempe, USA.

šŸ§¬ Skills

Dr. Jazowiecka-Rakus brings a wealth of expertise in cancer treatment, highlighted by her skills in oncolytic virotherapy, cancer immunotherapy, and advanced drug delivery systems. Her work with oncolytic virotherapy focuses on developing viral therapies that specifically target and destroy cancer cells, offering a promising alternative to traditional cancer treatments. In cancer immunotherapy, she integrates immune-enhancing agents to create therapies for advanced cancers. Her pioneering methods for stem cell-based drug delivery use mesenchymal stem cells as carriers for oncolytic viruses, targeting tumor cells more effectively. Additionally, she has developed nanocarrier drug formulations that improve the delivery and efficacy of drugs in cancer treatment.

Awards and Honors šŸ†

Dr. Jazowiecka-Rakusā€™s dedication to cancer research has earned her numerous accolades. Between 2017 and 2020, she was awarded a research grant by the International Center for Genetic Engineering and Biotechnology to study oncolytic melanoma therapy, underlining her impact in this vital area. Her scholarly contributions include 18 articles published in high-impact journals indexed in Web of Science and Scopus, reflecting her influence and recognition within the cancer research community. Her works have accumulated a citation index of over 431, showcasing the significant reach and impact of her research.

šŸŒ Memberships

Active in professional societies, Dr. Jazowiecka-Rakus is an auditor for the Association for the Support of Cancer Research in Gliwice, Poland, where she contributes to promoting research integrity and supporting advancements in cancer studies. She is also a member of the Polish Radiation Research Society based in Warsaw, where she engages with other professionals dedicated to improving cancer treatment and sharing knowledge within the field.

šŸ“š Teaching Experience

As an Assistant Professor, Dr. Jazowiecka-Rakus is committed to educating and mentoring the next generation of cancer researchers at the National Institute of Oncology. Her teaching covers essential aspects of oncology and medical biology, with a particular focus on innovative treatment strategies in cancer research. Through her courses and mentoring, she guides students in understanding the complexities of cancer treatment, encouraging them to pursue research that makes a real-world impact.

šŸ”¬ Research Focus

Dr. Jazowiecka-Rakusā€™s research centers on developing experimental therapies for aggressive cancers. Her work includes the creation of oncolytic myxoma virus constructs, which use mesenchymal stem cells as carriers to deliver viral therapies specifically targeting cancers such as pancreatic adenocarcinoma and glioma. She has developed advanced blood-brain barrier crossing techniques to treat glioma through intra-arterial delivery, offering a new method to target brain tumors effectively. Additionally, her research on 3D models for cancer uses spheroid and organoid models to test therapies for disseminated ovarian cancer, pushing the boundaries of cancer treatment with innovative laboratory models that mimic real-world conditions. Dr. Jazowiecka-Rakusā€™s interdisciplinary approach highlights her dedication to advancing the field of cancer therapy and improving patient outcomes.

ConclusionĀ 

In conclusion, Dr. Joanna Jazowiecka-Rakus exemplifies the qualities of an outstanding researcher through her innovative projects, significant contributions to cancer research, and a strong academic foundation. Her ongoing work and potential for future advancements make her a deserving candidate for the Best Researcher Award. Enhancing her publication record and pursuing patent opportunities would further solidify her standing as a leader in the field.

šŸ“š PublilcationĀ 

  • Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Bloodā€“Brain Barrier and Treat Murine Glioma
  • Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
  • Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
  • Removal of Heavy Metal Ions from Wastewaters: An Application of Sodium Trithiocarbonate and Wastewater Toxicity Assessment
  • COVID-19 Autopsies: A Case Series from Poland
  • Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
  • Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses

 

Dr Jeong Hwa Kim | Hemocompatibility Evaluation | Best Researcher Award

Posted on by sciencefather

Dr JeongHwa Kim | Hemocompatibility Evaluation | Best Researcher Award šŸ†

Research Fellow at University of Naples Federico II , ItalyšŸŽ“

Dr. JeongHwa Kim is a highly skilled researcher with a background in microbiology, biology education, and pharmacy. Currently serving as a Researcher at the Korea Testing Certification Institute since December 2020, she specializes in project administration, testing, and data analysis in fields such as cell toxicology, cell transformation, and hemocompatibility. Her research focuses on the interactions between medical devices and biological systems, contributing to medical safety and innovation.

 

Professional ProfileĀ 

  • ORCID
  • scopus
  • Google Scholar

EducationšŸŽ“

Dr. Kim completed her Ph.D. in Pharmacy at the University of Chungbuk (2013-2018), following a Masterā€™s degree in Biology Education (2010-2013), and a Bachelor’s degree in Microbiology (2003-2009), all from the University of Chungbuk. Her academic journey has provided her with a robust foundation in biological sciences and clinical research.

 

Ā šŸ’¼Work Experience

Since 2020, Dr. Kim has been working at the Korea Testing Certification Institute, where she leads various projects related to biomedical safety and testing. Her key responsibilities include project administration, conducting laboratory experiments, and performing data analysis. Her expertise in cell biology and hemocompatibility has been pivotal to the projects she handles.

Ā šŸ› ļøSkills

Dr. Kim is proficient in various experimental techniques, including DNA and RNA isolation, PCR, Western blotting, ELISA, and gel electrophoresis. Her expertise also extends to computational skills, with proficiency in the Microsoft Office suite, particularly Word and Excel, for data analysis and report preparation.

šŸ†Awards and Honors

Though specific awards and honors were not listed, Dr. Kim’s extensive publication record and her role as a leading researcher at the Korea Testing Certification Institute reflect her recognition in the scientific community.

Ā Research Focus šŸ”¬

Dr. Kimā€™s research is centered around hemocompatibility, cell transformation, and toxicity, with an emphasis on evaluating medical devices and materials for their biological safety. Her work, published in reputable journals, includes studies on the reactivity of animal-derived blood in medical tests and the evaluation of hemolysis and coagulation for medical device approval.

 

šŸ“–Publications :Ā 

šŸ§Ŗ Comparative Study on the Responsiveness of Different Species to Coagulation and Complement for Hemocompatibility Evaluation
Kim, J., Kim, G., Lim, J., Eom, J., Kim, T.
Journal: Applied Sciences (Switzerland)
Year: 2024
Volume: 14(15), 6721

šŸ”¬ Effectiveness of Erythrocyte Morphology Observation as an Indicator for the Selection and Qualification of Blood in a Mechanically Induced Hemolysis Test
Kim, J., Kim, T., Kim, S., Eom, J., Kim, T.
Journal: Applied Sciences (Switzerland)
Year: 2024
Volume: 14(11), 4695